Literature DB >> 21099664

Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors.

Maria Salgado1, Gregory D Kirk, Andrea Cox, Alleluiah Rutebemberwa, Yvonne Higgins, Jacquie Astemborski, David L Thomas, Chloe L Thio, Mark S Sulkowski, Joel N Blankson.   

Abstract

We tested the hypothesis that a single nucleotide polymorphism (SNP) located near the interleukin-28B gene is associated with the control of hepatitis C virus and HIV-1 replication in elite controllers/suppressors. We show here that the protective genotype is not overrepresented in elite controllers/suppressors compared with HIV-1-seronegative patients and HIV-1-infected patients with viral loads more than 10 000 copies/ml. Thus, it appears that this SNP is not associated with the elite control of HIV-1 infection.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21099664      PMCID： PMC3158988          DOI： 10.1097/QAD.0b013e328341b86a

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  12 in total

1.  IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.

Authors:  Maureen P Martin; Ying Qi; James J Goedert; Shehnaz K Hussain; Gregory D Kirk; W Keith Hoots; Susan Buchbinder; Mary Carrington; Chloe L Thio
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

2.  Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

Authors:  Norma I Rallón; Susanna Naggie; José M Benito; José Medrano; Clara Restrepo; David Goldstein; Kevin V Shianna; Eugenia Vispo; Alex Thompson; John McHutchison; Vincent Soriano
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

3.  Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.

Authors:  R S Garfein; D Vlahov; N Galai; M C Doherty; K E Nelson
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

4.  Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations.

Authors:  K Cao; J Hollenbach; X Shi; W Shi; M Chopek; M A Fernández-Viña
Journal:  Hum Immunol       Date:  2001-09       Impact factor: 2.850

5.  Hepatitis C infection in HIV-1 natural viral suppressors.

Authors:  Mohammad M Sajadi; Nahzinine Shakeri; Rohit Talwani; Robert R Redfield
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

6.  HLA-Cw*04 and hepatitis C virus persistence.

Authors:  Chloe L Thio; Xiaojiang Gao; James J Goedert; David Vlahov; Kenrad E Nelson; Margaret W Hilgartner; Stephen J O'Brien; Peter Karacki; Jacquie Astemborski; Mary Carrington; David L Thomas
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 7.  Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?

Authors:  Joel N Blankson
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

8.  Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?

Authors:  Cécile Goujard; Marie-Laure Chaix; Olivier Lambotte; Christiane Deveau; Martine Sinet; Julien Guergnon; Valérie Courgnaud; Christine Rouzioux; Jean-François Delfraissy; Alain Venet; Laurence Meyer
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

Review 9.  Elite control of HIV infection: implications for vaccine design.

Authors:  B M Baker; B L Block; A C Rothchild; B D Walker
Journal:  Expert Opin Biol Ther       Date:  2009-01       Impact factor: 4.388

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962
View more
  10 in total

1.  IL28B genotype does not correlate with HIV control in African Americans.

Authors:  Mohammad M Sajadi; Nahzinine Shakeri; Rohit Talwani; Charles D Howell; Ruth Pakyz; Robert R Redfield; Afshin Parsa
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

2.  HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.

Authors:  B Dominguez-Molina; L Tarancon-Diez; S Hua; C Abad-Molina; E Rodriguez-Gallego; K Machmach; F Vidal; C Tural; S Moreno; J M Goñi; E Ramírez de Arellano; M Del Val; M F Gonzalez-Escribano; J Del Romero; C Rodriguez; L Capa; P Viciana; J Alcamí; X G Yu; B D Walker; Manuel Leal; M Lichterfeld; E Ruiz-Mateos
Journal:  Clin Infect Dis       Date:  2016-12-16       Impact factor: 9.079

Review 3.  HIV Diagnosis and Treatment through Advanced Technologies.

Authors:  Hafiza Fizzah Zulfiqar; Aneeqa Javed; Bakht Afroze; Qurban Ali; Khadija Akbar; Tariq Nadeem; Muhammad Adeel Rana; Zaheer Ahmad Nazar; Idrees Ahmad Nasir; Tayyab Husnain
Journal:  Front Public Health       Date:  2017-03-07

4.  Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers.

Authors:  Alice K Asher; Glenn-Milo Santos; Jennifer Evans; Emily K Dokubo; Tzong-Hae Lee; Jeffrey N Martin; Steven G Deeks; Leslie H Tobler; Michael Busch; Peter W Hunt; Kimberly Page
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

Review 5.  IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.

Authors:  Christoph T Berger; Arthur Y Kim
Journal:  Infect Dis Clin North Am       Date:  2012-12       Impact factor: 5.982

6.  Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs.

Authors:  Ene-Ly Jõgeda; Radko Avi; Merit Pauskar; Eveli Kallas; Tõnis Karki; Don Des Jarlais; Anneli Uusküla; Karolin Toompere; Irja Lutsar; Kristi Huik
Journal:  J Med Virol       Date:  2018-08-16       Impact factor: 2.327

7.  Candida esophagitis in a human immunodeficiency virus-1-positive elite controller with hepatitis C virus cirrhosis.

Authors:  Anders Chen; Eugenie Shieh; Sherilyn Brinkley; Joel N Blankson
Journal:  Open Forum Infect Dis       Date:  2014-12-23       Impact factor: 3.835

Review 8.  Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.

Authors:  S Chinnaswamy
Journal:  Genes Immun       Date:  2016-06-09       Impact factor: 2.676

9.  Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study.

Authors:  Beatriz Dominguez-Molina; Laura Tarancon-Diez; Yusnelkis Milanés-Guisado; Miguel Genebat; Salvador Resino; Carmen Rodriguez; Juan Gonzalez-García; Norma Rallón; Maria Pernas; Concepción Casado; Cecilio Lopez-Galíndez; Agathe León; Jose M Benito; Felipe García; Jorge Del Romero; Pompeyo Viciana; Luis F Lopez-Cortes; Manuel Leal; Ezequiel Ruiz-Mateos
Journal:  J Int AIDS Soc       Date:  2020-09       Impact factor: 5.396

10.  Interferon lambda rs368234815 ΔG/ΔG is associated with higher CD4+:CD8+ T-cell ratio in treated HIV-1 infection.

Authors:  Inês T Freitas; Willard Tinago; Hirofumi Sawa; Julie McAndrews; Brenda Doak; Charlotte Prior-Fuller; Gerard Sheehan; John S Lambert; Eavan Muldoon; Aoife G Cotter; William W Hall; Patrick W G Mallon; Michael J Carr
Journal:  AIDS Res Ther       Date:  2020-04-15       Impact factor: 2.250
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.